CWA Asset Management Group LLC Sells 21,081 Shares of Johnson & Johnson $JNJ

CWA Asset Management Group LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 17.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,944 shares of the company’s stock after selling 21,081 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of CWA Asset Management Group LLC’s investment portfolio, making the stock its 29th biggest holding. CWA Asset Management Group LLC’s holdings in Johnson & Johnson were worth $18,532,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Ramsey Quantitative Systems bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $185,000. Stone Summit Wealth LLC lifted its stake in Johnson & Johnson by 14.6% during the 3rd quarter. Stone Summit Wealth LLC now owns 4,195 shares of the company’s stock valued at $778,000 after acquiring an additional 535 shares in the last quarter. Nabity Jensen Investment Management Inc boosted its holdings in Johnson & Johnson by 1.5% during the 3rd quarter. Nabity Jensen Investment Management Inc now owns 4,528 shares of the company’s stock worth $840,000 after acquiring an additional 68 shares during the last quarter. Powers Advisory Group LLC raised its holdings in shares of Johnson & Johnson by 3.7% in the third quarter. Powers Advisory Group LLC now owns 10,173 shares of the company’s stock valued at $1,886,000 after purchasing an additional 360 shares during the last quarter. Finally, Allen Wealth Management LLC lifted its position in shares of Johnson & Johnson by 257.1% during the third quarter. Allen Wealth Management LLC now owns 10,927 shares of the company’s stock valued at $2,026,000 after purchasing an additional 7,867 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase‑2 success for nipocalimab and plan to start Phase‑3 — J&J reported topline JASMINE results showing nipocalimab met primary and key secondary endpoints in systemic lupus erythematosus (SLE), including signals for steroid‑sparing benefit; management will advance the program into Phase‑3, which materially derisks a late‑stage pipeline opportunity and supports future revenue upside. Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker…
• Positive Sentiment: MedTech regulatory progress — Johnson & Johnson MedTech submitted its Ottava surgical robot to the U.S. FDA, signaling potential future product rollout in a higher‑growth surgical robotics market and strengthening the medtech revenue runway. Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Positive Sentiment: EMA filing for Tecvayli + Darzalex combo — J&J submitted an application to the European Medicines Agency for teclistamab (Tecvayli) in combination with daratumumab (Darzalex) SC for relapsed/refractory multiple myeloma, which could expand label/use and drive incremental oncology sales in Europe. Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI® (teclistamab)…
• Positive Sentiment: Broker support lifts sentiment — Wolfe Research raised its JNJ price target to $240 and Barclays raised its target to $217 (while keeping an Equal Weight), and Scotiabank maintained a Buy rating; these actions provide incremental credibility to upside views and can attract institutional flows. Wolfe Research Increases Johnson & Johnson Price Target to $240.00
• Neutral Sentiment: Market commentary on valuation and recent run-up — Several pieces assess whether J&J remains attractive after a strong one‑year gain and include it on dividend‑growth lists; these articles frame investor debate over valuation versus defensive dividend appeal rather than introduce new fundamental catalysts. Is Johnson & Johnson (JNJ) Still Attractive After A 44% One Year Share Price Gain
• Neutral Sentiment: Analyst/sector comparisons and themes — Industry write‑ups compare JNJ vs. peers (e.g., AstraZeneca), and broader analyst blogs highlight AI and medtech trends; useful for positioning but less likely to move the stock near‑term than the clinical/regulatory news. The Zacks Analyst Blog: Eli Lilly, Medtronic, Intuitive Surgical, Regeneron and Johnson & Johnson

Johnson & Johnson Stock Up 1.3%

Shares of NYSE JNJ opened at $207.47 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $499.85 billion, a PE ratio of 20.03, a P/E/G ratio of 2.10 and a beta of 0.34. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The business’s fifty day moving average price is $202.23 and its 200-day moving average price is $184.00.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $212.62.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.